Abstract:1667 Substitutions and deletions in exons in the tyrosine kinase domain of the EGFR gene (exons 18 to 24) in lung tumors have been associated with sensitivity to molecular target therapeutic agents classified as tyrosine kinase inhibitors (TKIs). Among the TKIs are gefitinib and erlotinib, which produce objective responses in 10-20% of advanced NSCLC patients after chemotherapy. Erlotinib prolongs survival in these patients. The relationship between mutation and response and survival is imperfect, suggesting that other factors may play a role in determining sensitivity to TKIs. Recently we found EGFR amplification to be frequent in NSCLC (13%) and to be related to gefitinib response and survival. In this report, we examined genomic DNAs from 78 NSCLC and 20 SCLC lung cancer cell lines. Exons 18-21 of the tyrosine kinase domain were amplified and sequenced for the presence of mutations. Mutations were found in none of the SCLC lines and 8 of 78 NSCLC lines (10%), namely NCI-H820, NCI-H1650, NCI-H1975, NCI-H3255, HCC827, HCC2279, HCC2935 and HCC4006. These cell lines were initiated from 7 Caucasian patients and one of Oriental origin. Most patients were light or never smokers. Six of the mutations were deletions in exon 19 and two were the L858R point mutation in exon 21. Dual color fluorescence in situ hybridization analysis was performed in 35 NSCLC lines using the EGFR/CEP 7 probe (Vysis/Abbott). EGFR gene amplification was identified in 7 of these lines, all carrying EGFR mutations. H3255, HCC827, HCC2259, and HCC4006 had large, clustered gene amplification in all cells; H1650 had focal gene amplification with large gene clusters in approximately 30% of cells; NCI-H820 and HCC2935 showed small gene clusters in interphase nuclei and apparently normal metaphase chromosomes, supporting the hypothesis that rearranged chromosomes harbor gene duplications. The remaining mutated line, NCI-1975 had no evidence of amplification. Chromosomes harboring large amplicons including EGFR were distinct among the lines. H3255 showed gene clusters in two distinct chromosomes, a large der(7) with three layers of gene clusters and a large metacentric with numerous layers of gene clusters in both arms. HCC827, HCC4006 and H1650 carried the EGFR amplification in the long arm of der(7) with large gene clusters interspaced by centromeric sequences. Preliminary in vitro testing showed that the majority of the mutated lines were sensitive to gefitinib and that there was a correlation between gefitinib sensitivity and the degree of gene amplification. These results identified gene amplification as frequently associated with mutations in the tyrosine kinase domain of the EGFR gene in NSCLC cell lines and support the role of both amplification and mutation in the sensitivity to TKIs.

Mutations of the epidermal growth factor receptor gene in NSCLC patients.

[Clinicopathological Features Associated with EGFR Gene Mutation in Non-Small Cell Lung Cancer Patients].

Prevalence of Mutation in the Epidermal Growth Factor Receptor Gene in Chinese Patients with Non-small Cell Lung Cancer

Relationship Between Mutations of Epidermal Growth Factor Receptor in the Plasma and Pleural Effusion and Responses to Gefitinib in Advanced Pretreated Non-Small Cell Lung Cancer

Prediction of Epidermal Growth Factor Receptor Mutations in the Plasma/pleural Effusion to Efficacy of Gefitinib Treatment in Advanced Non-Small Cell Lung Cancer.

[Relationship Between Mutations of Epidermal Growth Factor Receptor Gene and Clinicopathologic Features of Non-Small Cell Lung Cancers].

Epidermal growth factor receptor mutations in lung cancer

P3-015: Clinicopathologic Features and Epidermal Growth Factor Receptor Mutations Associated with Epithelial-Mesenchymal Transition in Non-Small Cell Lung Cancer

A Novel Acquired EGFR-SEPT14 Fusion Confers Differential Drug Resistance to EGFR Inhibitors in Lung Adenocarcinoma.

Clinical significance of EGFR mutations in non-small cell lung cancer

Egfr Mutations and the Correlation with Gefitinib Therapy in Chinese Nsclc - A Systematic Review Based on Individual Patient Data from 5 Medical Centers in China.

Gefitinib-Sensitive Mutations of the Epidermal Growth Factor Receptor Tyrosine Kinase Domain in Chinese Patients with Non–Small Cell Lung Cancer

[Epidermal Growth Factor Receptor Gene Mutations and Clinicopathologic Correlation in 309 Patients with Non-Small Cell Lung Cancer].

Clinical Characteristics and Survival Outcomes for Non-Small-Cell Lung Cancer Patients with Epidermal Growth Factor Receptor Double Mutations

P1.07-024 EGFR Mutations in Small Cell Lung Cancer (SCLC): Genetic Heterogeneity and Prognostic Impact: Topic: Molecular Changes

A Rare Epidermal Growth Factor Receptor G735R Mutation in Advanced Non-Small-Cell Lung Cancer with Poor Response to Gefitinib

Somatic Mutations of the Epidermal Growth Factor Receptor and Non-Small-cell Lung Cancer

Gefitinib sensitivity in non-small cell lung cancer (NSCLC) cell lines associates with mutation and amplification of the epidermal growth factor receptor (EGFR) gene

Clinicopathological features of Chinese lung cancer patients with epidermal growth factor receptor mutation.

The Status of Epidermal Growth Factor Receptor (EGFR) Mutations at Exon 19 and 21 in Chinese Patients with NSCLC

The Predictive Value of Uncommon EGFR Mutation in Patients with Non-Small-cell Lung Cancer.